Quotient Limited (QTNT)
| Sector • Healthcare Industry • Biotechnology & Pharmaceuticals |
| Industry • Biotechnology & Pharmaceuticals |
| Sector • Healthcare |
Very noticeable Decline in revenue at QTNT in the first quarter of 2023 earnings season
QTNT announced first quarter of 2023 operating shortfall of $-25.795 million
Published 2022-08-13T03:26:39+00:00
Goran Soko / CSIMarket.com Contributer
![Autosample_takes_a_By_Hey_Paul_(originally_posted_to_Flickr_as_image8)_[CC-BY-SA-2.0_(http_creativecommons.org_licenses_by-sa_2.0)]_via_Wikimedia_Commons](../news/img/healthcare/Autosample_takes_a_By_Hey_Paul_(originally_posted_to_Flickr_as_image8)_[CC-BY-SA-2.0_(http_creativecommons.org_licenses_by-sa_2.0)]_via_Wikimedia_Commons.jpg "Autosample_takes_a_By_Hey_Paul_(originally_posted_to_Flickr_as_image8)_[CC-BY-SA-2.0_(http_creativecommons.org_licenses_by-sa_2.0)]_via_Wikimedia_Commons")
Lower orders led to diminishing revenue and larger deficit, in the most recent fiscal period QTNT decreased a loss per share to $-0.37 per share, while Revenue went down by -8.549 % to $8.81 million, year on year.In the prior quarter the company realized Revenue of $11.21 million and bottom line of $-0.40 per share.
In the most recent fiscal period Quotient Limited reported net deficit of $-38.868 million, instead of deficit of $-40.871 million in the similar quarter a year ago.
Quotient Limited is expected to report next financial results on June 27, 2023.